Joel Marcus - Intra-Cellular Ther Director

ITCI
 Stock
  

USD 55.17  1.91  3.35%   

  Director
Mr. Joel S. Marcus J.D., CPA is an Independent Director of IntraCellular Therapies, Inc. Mr. Marcus became a director of the Company following the Merger that occurred in August 2013 and has served on the board of directors of ITI since April 2006. Mr. Marcus is the Executive Chairman and Founder of Alexandria Real Estate Equities, Inc., or Alexandria, an urban office REIT focused on worldclass collaborative life science and technology campuses in AAA innovation cluster locations. Mr. Marcus cofounded Alexandria in 1994 with a business plan and 19 million in seed capital and has led its growth into an SP 500 company. Alexandria has a significant market presence in key locations, including Greater Boston, San Francisco, New York City, San Diego, Seattle, Maryland, and Research Triangle Park. In 1996, Mr. Marcus also founded Alexandria Venture Investments, the companys strategic VC arm. Prior to cofounding Alexandria, Mr. Marcus had an extensive legal career specializing in corporate finance and capital markets, VC, and mergers and acquisitions, with expertise in the biopharmaceutical industry. He was also a practicing certified public accountant and tax manager with Arthur Young Co., where he focused on the financing and taxation of REITs. Mr. Marcus was one of the original architects and cofounders of Accelerator Corporationrationration and AgTech Accelerator, for which he serves on the board of directors. He also serves on the boards of Applied Therapeutics Inc., Boragen, Inc., Frequency Therapeutics, MeiraGTx Holdings plc and Yumanity Therapeutics. Mr. Marcus previously served as a director of Atara Biotherapeutics, Inc
Age: 70  Director Since 2014      
646 440-9333  www.intracellulartherapies.com
Marcus is a recipient of the Ernst & Young Entrepreneur of the Year Award . He was awarded his undergraduate and Juris Doctor degrees at the University of California, Los Angeles.

Joel Marcus Latest Insider Activity

Tracking and analyzing the buying and selling activities of Joel Marcus against Intra-Cellular Ther stock is an integral part of due diligence when investing in Intra-Cellular Ther. Joel Marcus insider activity provides valuable insight into whether Intra-Cellular Ther is net buyers or sellers over its current business cycle. Note, Intra-Cellular Ther insiders must abide by specific rules, including filing SEC forms every time they buy or sell Intra-Cellular Ther'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Intra-Cellular Ther Management Efficiency

Intra-Cellular Ther has return on total asset (ROA) of (29.58) % which means that it has lost $29.58 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (52.87) %, meaning that it created substantial loss on money invested by shareholders. Intra-Cellular Ther management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Investment is estimated to decrease to -57.36. The current Return on Average Assets is estimated to decrease to -0.52. Intra-Cellular Ther Asset Turnover is most likely to slightly decrease in the upcoming years. The last year's value of Asset Turnover was reported at 0.14. The current Tangible Assets Book Value per Share is estimated to increase to 6.98, while Total Assets are projected to decrease to roughly 435.4 M.
The company currently holds 25.41 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. Intra-Cellular Ther has a current ratio of 8.58, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Intra-Cellular Ther until it has trouble settling it off, either with new capital or with free cash flow. So, Intra-Cellular Ther's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Intra-Cellular Ther sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Intra-Cellular to invest in growth at high rates of return. When we think about Intra-Cellular Ther's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing few of many executives

DIRECTOR Since

Barry DillerCoca-Cola
2002
Michele BurnsCisco Systems
2003
Mark McClellanJohnson Johnson
2013
Ian DavisJohnson Johnson
2010
James McNerneyProcter Gamble
2007
William PerezJohnson Johnson
2007
Scott GottliebPfizer Inc
2019
Dean SuntupBellus Health
2013
Andrew WilsonIntel Corp
2017
Joseph JimenezProcter Gamble
2021
John StantonMicrosoft Corp
2014
Stacy SmithIntel Corp
2016
Penny PritzkerMicrosoft Corp
2017
Mason MorfitMicrosoft Corp
N/A
Susan LindquistJohnson Johnson
2004
Reed HundtIntel Corp
2001
Gary ChengDupont Denemours
N/A
Frederick WaddellInternational Business Machines
2017
Richard DaleyCoca-Cola
2011
Mary BeckerleJohnson Johnson
2015
Stephen SangerPfizer Inc
2009
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York. Intra-Cellular Ther operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 512 people. Intra-Cellular Ther (ITCI) is traded on NASDAQ Exchange in USA. It is located in 430 East 29th Street, New York, NY 10016, United States and employs 512 people. Intra-Cellular Ther is listed under Pharmaceutical Products category by Fama And French industry classification.

Intra-Cellular Ther Leadership Team

Elected by the shareholders, the Intra-Cellular Ther's board of directors comprises two types of representatives: Intra-Cellular Ther inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Intra-Cellular. The board's role is to monitor Intra-Cellular Ther's management team and ensure that shareholders' interests are well served. Intra-Cellular Ther's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Intra-Cellular Ther's outside directors are responsible for providing unbiased perspectives on the board's policies.
Lawrence Wennogle, Vice President of Drug Discovery
Suresh Durgam, Senior Vice President Late Stage Clinical Development and Medical Affairs
Christopher Alafi, Director
Michael Rawlins, Director
Robert Nostrand, Independent Director
Richard Lerner, Director
Robert Davis, Senior Vice President and Chief Scientific Officer
Allen Fienberg, Co-Founder and VP of Bus. Devel.
Mark Neumann, Executive Vice President Chief Commercial Officer
Michael Halstead, Sr. VP, General Counsel and Secretary
Sharon Mates, Co-Founder, Chairman, CEO and Pres
Andrew Satlin, Executive Vice President and Chief Medical Officer
Juan Sanchez, Vice President - Corporate Communications and Investor Relations
Rory Riggs, Independent Director
John Bardi, Senior Vice President - Market Access, Policy and Government Affairs
Joel Marcus, Director
Kimberly Vanover, VP of Clinical Devel.
Michael Olchaskey, Senior Vice President Head of Regulatory Affairs
Lawrence Hineline, Vice President and CFO

Intra-Cellular Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Intra-Cellular Ther a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Intra-Cellular Ther without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Piotroski F Score Now

   

Piotroski F Score

Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Intra-Cellular Ther using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Risk vs Return Analysis. Note that the Intra-Cellular Ther information on this page should be used as a complementary analysis to other Intra-Cellular Ther's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Complementary Tools for Intra-Cellular Stock analysis

When running Intra-Cellular Ther price analysis, check to measure Intra-Cellular Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intra-Cellular Ther is operating at the current time. Most of Intra-Cellular Ther's value examination focuses on studying past and present price action to predict the probability of Intra-Cellular Ther's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Intra-Cellular Ther's price. Additionally, you may evaluate how the addition of Intra-Cellular Ther to your portfolios can decrease your overall portfolio volatility.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Is Intra-Cellular Ther's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intra-Cellular Ther. If investors know Intra-Cellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intra-Cellular Ther listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
5.2 B
Quarterly Revenue Growth YOY
1.2
Return On Assets
-0.25
Return On Equity
-0.43
The market value of Intra-Cellular Ther is measured differently than its book value, which is the value of Intra-Cellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intra-Cellular Ther's value that differs from its market value or its book value, called intrinsic value, which is Intra-Cellular Ther's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intra-Cellular Ther's market value can be influenced by many factors that don't directly affect Intra-Cellular Ther's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intra-Cellular Ther's value and its price as these two are different measures arrived at by different means. Investors typically determine Intra-Cellular Ther value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intra-Cellular Ther's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.